Boswellia — Research Profile

AKBA (acetyl-11-keto-beta-boswellic acid) is the most potent anti-inflammatory compound in boswellia. It directly inhibits the 5-LOX enzyme, blocking leukotriene production. Clinical meta-analyses confirm standardized boswellia extracts significantly improve osteoarthritis outcomes. ^[1] Look for extracts standardized to at least 30% AKBA for maximum anti-inflammatory benefit.

Boswellia inhibits 5-LOX (blocking leukotrienes) while NSAIDs inhibit COX enzymes (blocking prostaglandins). Boswellia does not cause the GI ulceration associated with NSAIDs. Clinical trials suggest comparable pain relief for mild-moderate osteoarthritis, though NSAIDs may be faster-acting for acute pain.

Yes, boswellia and turmeric/curcumin target different inflammatory pathways (5-LOX vs. NF-kB/COX-2) and are commonly combined. Several commercial joint supplements combine both. No significant adverse interactions have been reported in clinical studies.

Oral standardized oleogum-resin extracts are the forms tested in controlled trials. Enriched formulations such as Aflapin and 5-Loxin (30% AKBA) at 100 to 250 mg/day performed comparably or better than generic extracts, and Aflapin showed faster symptom onset than 5-Loxin in one direct comparison. No single branded form has been proven definitively superior for long-term outcomes.

The strongest evidence is for knee osteoarthritis: a meta-analysis of seven trials (545 patients) found significant improvements in pain (WOMAC pain WMD -14.22), stiffness and physical function versus placebo. A separate meta-analysis in type 2 diabetes reported a significant HbA1c reduction (SMD -1.01) and lower total cholesterol, triglycerides and LDL, though the fasting-glucose change was not statistically significant. Other traditional uses have weaker clinical support.

Osteoarthritis trials used enriched extracts at 100 to 250 mg/day (for example 5-Loxin 100 or 250 mg, or Aflapin 100 mg). For non-enriched standard extracts, NIH LiverTox cites a usual dose of 250 to 500 mg taken two or three times daily. No single dose fits all products because potency depends on the standardized boswellic-acid content, so dose to the labeled AKBA/boswellic-acid level rather than raw milligrams.

Clinical trials dosed boswellia daily, often as divided doses of 250 to 500 mg two or three times a day, without comparing any specific time of day, so an optimal timing has not been established. Because mild gastrointestinal upset is the most common complaint, taking it with food is a reasonable way to reduce that.

Reported side effects are few and mostly mild, transient gastrointestinal symptoms such as nausea, diarrhea or constipation, and in controlled trials adverse events were no more frequent than with placebo. NIH's LiverTox review notes that hypersensitivity reactions can occur but says their frequency is not known. Memorial Sloan Kettering's monograph documents allergic skin reactions, chiefly allergic contact dermatitis after topical boswellia products, while rating oral use as generally well tolerated; serious or liver-related adverse effects have not been convincingly documented.

No clinically established drug interactions are documented for boswellia in the NIH LiverTox review. Because boswellic acids inhibit 5-lipoxygenase and reduce inflammatory mediators, an additive effect with anti-inflammatory drugs is biologically plausible but has not been demonstrated. Its measured HbA1c-lowering effect means people taking diabetes medication should monitor blood glucose for additive lowering.

The best-supported candidates are adults with mild-to-moderate knee osteoarthritis seeking pain and function relief, since that is where controlled-trial evidence is strongest. People with type 2 diabetes may see a modest glycemic benefit but should watch for additive effects with their medication. It is not recommended during pregnancy or breastfeeding because human safety data in those groups are lacking.

In knee osteoarthritis trials, standardized extracts such as 5-Loxin (30% AKBA) at 250 mg/day and Aflapin at 100 mg/day produced statistically significant reductions in pain and improvements in function as early as 7 days, though most benefit accumulated over the full 90-day studies. A meta-analysis of seven trials concluded that at least about 4 weeks of use is needed before judging response. Onset is fastest with the more enriched formulations.

The longest controlled trials ran up to 180 days (Aflapin 100 mg/day), with hematology, serum biochemistry, urinalysis and vital signs unchanged versus placebo. NIH's LiverTox rates Boswellia serrata as an unlikely cause of liver injury (likelihood score E) and reports no serum enzyme elevations during therapy. Data beyond about 6 months are limited, so continuous multi-year use has not been formally studied.

No toxic threshold or formal upper limit has been established for boswellia in humans. Controlled trials using up to 250 mg of 30%-AKBA extract, and NIH LiverTox's cited range of 250 to 500 mg two or three times daily of standard extract, reported safety parameters essentially unchanged from placebo. At higher intakes the main reported issue is mild gastrointestinal upset rather than organ toxicity.

Boswellia is most often combined with curcumin for knee osteoarthritis; a meta-analysis of 11 trials found both curcuminoid and boswellia formulations more effective than placebo for pain and function, although overall trial quality was low. No specific combination has been shown to outperform boswellia alone in head-to-head trials. Because boswellia lowered HbA1c in diabetic patients, stacking it with other glucose-lowering supplements could have additive effects worth monitoring.

The active constituents are boswellic acids, chiefly AKBA (3-O-acetyl-11-keto-beta-boswellic acid), so choose an oleogum-resin extract that states its boswellic-acid or AKBA content. The best-documented products are the standardized extracts used in trials, such as 5-Loxin (standardized to 30% AKBA) and Aflapin. A labeled standardization percentage is more meaningful than raw milligrams of unspecified powder.